| Specificity and Sensitivity of different membrane molecules used to detect CTC |
| Marker |
Tumor tissue |
% cases in which CTC have been reported |
false positive in healthy donors |
References |
| |
|
|
|
|
| EpCAM |
Lung, Prostate, Colon, Breast, Bladder |
Breast cancer: 70% (n=92) |
0 (n=5) |
[19-22] |
| EphB4 |
Breast, Colorectal, Head & Neck |
Breast cancer: 77.5% (n=40) |
0 (n=47) |
[41-43] |
| EGFR |
Breast, Colon, Gastric |
Colon cancer: 18% (n=19) |
0.5% (n=38) |
[54-60] |
| CEA |
Breast, Gastric, Pancreatic |
Colon cancer: 66% (n=25) |
20% (n=10) |
[47, 54, 55, 65-68] |
| HER2 |
Breast, Gastric |
Advanced breast cancer:
37% (n=15)
Early stage breast cancer:
48.6% (n=35) |
0 (n=42) |
[48, 49, 51, 52] |
| MUC-1 |
Colorectal, Ovarian, Breast, Prostate |
Breast cancer: 88.2% (n=34) |
24% (n=29) |
[67, 71-75] |
| N - Patient number involved in study |
|
